Faricimab, a bispecific antibody targeting both VEGF-A and angiopoietin-2 (Ang-2), has shown promising results in age-related macular degeneration [5] and diabetic macular edema [6, 7]. Here, ANGPT2 is linked to diabetic macular edema.